StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Biogen (BIIB) PT Lowered to $390 at Oppenheimer
October 20, 2021 6:05 PM
Oppenheimer analyst Jay Olson lowered the price target on Biogen (NASDAQ: BIIB) to $390.00 (from $450.00) while maintaining an Outperform ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Biogen (BIIB) PT Lowered to $386 at Needham & Company
October 21, 2021 6:26 AM
Biogen (BIIB) PT Lowered to $375 at Cowen
October 20, 2021 5:59 PM
Form 10-Q BIOGEN INC. For: Sep 30
October 20, 2021 4:21 PM
Biogen (BIIB) PT Lowered to $261 at Wedbush
October 20, 2021 1:42 PM
Biogen (BIIB) Stock Edges Higher on Strong Earnings, Sales of New Alzheimer Drug Just $300k
October 20, 2021 9:00 AM
Long-term Prospects for Biogen’s (BIIB) Aduhelm Remain Key Question - Analyst
October 20, 2021 8:21 AM
Form 8-K BIOGEN INC. For: Oct 20
October 20, 2021 7:10 AM
Biogen banks on government coverage to restart stalled Alzheimer's drug sales
October 20, 2021 7:07 AM
